Key result
Endothelial dysfunction serves as an early indicator of atherosclerosis, and its management through lifestyle modifications and pharmacological therapies can delay cardiovascular disease progression.
Understanding and targeting endothelial dysfunction provides a clinical opportunity to detect early cardiovascular disease, stratify risk, and assess response to primary and secondary preventive treatments.
Answers are grounded in this paper and cite their sources.
Endothelial dysfunction assessment may aid early risk stratification in practice; leaves open whether targeted therapies improve outcomes in prospective trials.
Atherosclerosis is a chronic progressive vascular disease. It starts early in life, has a long asymptomatic phase, and a progression accelerated by various cardiovascular risk factors. The endothelium is an active inner layer of the blood vessel. It generates many factors that regulate vascular tone, the adhesion of circulating blood cells, smooth muscle proliferation, and inflammation, which are the key mechanisms of atherosclerosis and can contribute to the development of cardiovascular events. There is growing evidence that functional impairment of the endothelium is one of the first recognizable signs of development of atherosclerosis and is present long before the occurrence of atherosclerotic cardiovascular disease. Therefore, understanding the endothelium's central role provides not only insights into pathophysiology, but also a possible clinical opportunity to detect early disease, stratify cardiovascular risk, and assess response to treatments. In the present review, we will discuss the clinical implications of endothelial function as well as the therapeutic issues for endothelial dysfunction in cardiovascular disease as primary and secondary endothelial therapy.
No takes yet. Share an insight, caveat, or question.
Park et al. (2015) conducted a review in Endothelial Dysfunction and Cardiovascular Disease. Endothelial dysfunction serves as an early indicator of atherosclerosis, and its management through lifestyle modifications and pharmacological therapies can delay cardiovascular disease progression.
Synapse has enriched 10 related papers. Consider them for comparative context: